Darren Gannuch, MD
Sleep Medicine · Huntsville, ALNPI 1669401709
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 374 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 28.8% of the total.
Across 374 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$2K
- Harmony Biosciences LLC$2K
- Axsome Therapeutics, Inc.$564
- UCB, Inc.$414
- Avadel CNS Pharmaceuticals, LLC$334
- Supernus Pharmaceuticals, Inc.$239
- plus $1K from 17 others
What the payments were for
- Consulting fees$1502%
- Food & beverage$6,43997%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 113 | $1,913 |
| Harmony Biosciences LLC | 81 | $1,710 |
| Axsome Therapeutics, Inc. | 28 | $564 |
| UCB, Inc. | 24 | $414 |
| Avadel CNS Pharmaceuticals, LLC | 21 | $334 |
| Supernus Pharmaceuticals, Inc. | 16 | $239 |
| Biohaven Pharmaceuticals, Inc. | 14 | $184 |
| SK Life Science, Inc. | 10 | $168 |
| Inspire Medical Systems, Inc. | 7 | $134 |
| Merck | 8 | $133 |
| Teva Pharmaceuticals USA, Inc. | 7 | $117 |
| Eisai Inc. | 7 | $101 |
| Sunovion Pharmaceuticals Inc. | 5 | $88 |
| Idorsia Pharmaceuticals US Inc | 5 | $74 |
| AstraZeneca | 4 | $72 |
| Lundbeck LLC | 3 | $70 |
| Lilly USA, LLC | 4 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $65 |
| Arbor Pharmaceuticals, Inc. | 4 | $59 |
| AbbVie | 4 | $53 |
| Amgen | 3 | $49 |
| 3b Medical, Inc. | 1 | $20 |
| Adamas Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,639 in reported general payments places this provider in the 60th percentile of 28 sleep medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 33 | $525,263 |
| WakixPitolisant Hcl | 17 | $185,448 |
| SunosiSolriamfetol Hcl | 13 | $10,702 |
| Armodafinil | 45 | $2,517 |
| Zolpidem Tartrate | 170 | $608 |
| Zaleplon | 91 | $392 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $376 |
| Trazodone Hcl | 45 | $371 |
| Gabapentin | 53 | $270 |
| Eszopiclone | 33 | $252 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 39 | $239 |
| Ropinirole Hcl | 40 | $233 |
| Methylphenidate Hcl | 12 | $177 |
| Clonazepam | 39 | $150 |
| Doxepin Hcl | 19 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $1,710 | $185,44817 claims |
| Axsome Therapeutics, Inc.Sunosi | $564 | $10,70213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 28 sleep medicine providers in Alabama.
Other sleep medicine in Huntsville
- James RoyHuntsville$823K
- Marijo-Anne MolinaHuntsville$5K
- Robert BussHuntsville$3K
- Edward TurpinHuntsville$0
- Michael LedetDaphne$795K
- Gordon WarnerCullman$100K
- James GeyerTuscaloosa$61K
- Ashwin AnanthFoley$57K
- Christopher HopeOpelika$32K
- Bahador TafazoliCullman$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.